Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Go back to Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease| Diversified Corporate Resources, Inc. (NASDAQ: IRD) | Delayed: 4.67 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.67 | 52 Week High | $0.02 | |||
| Open | $4.67 | 52 Week Low | $0.02 | |||
| Day High | $4.67 | P/E | N/A | |||
| Day Low | $4.67 | EPS | $0.00 | |||
| Volume | 1,028 | |||||
